CyFlow™ HLA-A2 Azide Free
| Antibody: | Yes |
| Antigen: | HLA-A2 |
| Application: | Flow cytometry, Immunoprecipitation |
| Clonality: | monoclonal |
| Clone: | BB7.2 |
| Field of Interest: | MHC |
| Format/Fluorochrome: | Azide Free |
| Isotype: | IgG2b |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | AT081139 |
For Research Use Only
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | HLA-A2 solubilised by papain |
| Background Information | HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant β2-microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumor defense. |
| Storage Buffer | The reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Parham P, Brodsky FM: Partial purification and some properties of BB7.2: A cytotoxic monoclonal antibody with specificity for HLA‑A2 and a variant of HLA‑A28. Hum Immunol. 1981 Dec; 3(4):277‑99. < PMID: 7035415 > | Pious D, Krangel MS, Dixon LL, Parham P, Strominger JL: HLA antigen structural gene mutants selected with an allospecific monoclonal antibody. Proc Natl Acad Sci USA. 1982 Dec; 79(24):7832‑6. < PMID: 6961455 > | Krangel MS, Taketani S, Pious D, Strominger JL: HLA‑A2 mutants immunoselected in vitro: Definition of residues contributing to an HLA‑A2‑specific serological determinant. J Exp Med. 1983 Jan 1; 157(1):324‑36. < PMID: 6184441 > | Taketani S, Krangel MS, Pious D, Strominger JL: Structural analysis of HLA‑A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA‑A2‑specific serological determinant. J Immunol. 1983 Dec; 131(6):2935‑8. < PMID: 6196407 > | Brenner MB, McLean J, Yang SY, van der Poel JJ, Pious D, Strominger JL: Clonal T lymphocyte recognition of the fine structure of the HLA‑A2 molecule. J Immunol. 1985 Jul; 135(1):384‑90. < PMID: 2582041 > | Scornik JC: HLA‑A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum Immunol. 1987 Apr; 18(4):277‑85. < PMID: 2437089 > | Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA‑A2 molecule. J Immunol. 1988 Oct 15; 141(8):2811‑8. < PMID: 2459229 > | Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA. 1989 Sep; 86(17):6719‑23. < PMID: 2672003 > | Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA‑A2. Hum Immunol. 1992 Mar; 33(3):185‑92. < PMID: 1377666 > | Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA‑A2.1‑restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun; 23(6):1215‑9. < PMID: 7684681 > | Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA‑A2 presents shared tumor‑associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993 Nov 15; 151(10):5481‑91. < PMID: 8228240 > | Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA‑A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct; 7(10):1599‑605. < PMID: 8562505 > | Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single‑chain HLA‑A2.1 molecule, with a cis active beta‑2‑microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996 Aug; 49(1):28‑37. < PMID: 8839773 > | Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P: Juvenile arthritis, HLA‑A2 and binding of DEK oncogene‑peptides. Hum Immunol. 1998 Jul; 59(7):443‑50. < PMID: 9684994 > | Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor‑specific, HLA Class‑I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999 Dec; 60(12):1195‑206. < PMID: 10626733 > | Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor‑specific CD8+ cytotoxic T lymphocytes by acid‑eluted peptide‑pulsed autologous dendritic cells. Obstet Gynecol. 2000 Sep; 96(3):422‑30. < PMID: 10960637 > | Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR‑SSP method for HLA‑A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006 Dec; 3(6):453‑8. < PMID: 17257499 >